NASDAQ$VERV
Verve Therapeutics Inc · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
Verve Therapeutics reported pipeline progress and financial results for Q2 2024.
Verve Therapeutics reported a net loss of $49.8 million for the second quarter of 2024. The company's cash, cash equivalents, and marketable securities totaled $575.9 million, expected to fund operations into late 2026. The Heart-2 Phase 1b clinical trial of VERVE-102 continues to progress, and the Phase 1b clinical trial for VERVE-201 is on track for the second half of 2024.
- Heart-2 clinical trial of VERVE-102 is enrolling in the U.K. and Canada, with Clinical Trial Application cleared in Australia.
- Initial data from the Heart-2 clinical trial and an update on the PCSK9 program are planned for the first half of 2025.
- Phase 1b clinical trial initiation for VERVE-201 is on track for the second half of 2024.
- Cash, cash equivalents, and marketable securities totaled $575.9 million, providing a cash runway into late 2026.
Headline financials
Revenue & EPS history
Verve Therapeutics · Revenue · Quarterly
$6.69M
Revenue by segment
Verve Therapeutics · $3.12M total across 1 segment · Q3 2023
- Collaboration Revenue$3.12M—100.0%
Forward guidance
Verve Therapeutics anticipates continued progress with its clinical trials and expects its current capital position to be sufficient to fund operations into late 2026.
Tailwinds
- Heart-2 clinical trial of VERVE-102 enrolling in the U.K. and Canada.
- Clinical Trial Application cleared in Australia for VERVE-102.
- Data update for Heart-2 and PCSK9 program planned for the first half of 2025.
- Phase 1b clinical trial initiation for VERVE-201 on track for the second half of 2024.
- Cash runway expected into late 2026.
Headwinds
- Enrollment remains paused in the Phase 1b Heart-1 clinical trial.
- Ongoing investigation of observed laboratory abnormalities in the Heart-1 trial.
- Uncertainty regarding the potential path forward for VERVE-101 with regulatory authorities.
- Dependence on regulatory clearances for initiating the VERVE-201 Phase 1b clinical trial.
- Risks associated with clinical trials and regulatory approvals.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 17 quarterly earnings reports · overlaid with Q2 2024
-1.0%
Avg return
Earnings day
+0.3%
Avg return
5 days after
-3.8%
Avg return
30 days after
47%
8 / 17 earnings
Positive
+24.4%
Q4 2023
Best reaction
-34.2%
Q3 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | — | — | — | |
| Q1 2025 | +3.4% | +5.0% | +48.1% | |
| Q4 2025 | -1.7% | -2.9% | -16.3% | |
| Q3 2024 | +6.0% | +4.5% | +1.0% | |
| Q2 2024 | -12.1% | -20.8% | -1.6% | |
| Q1 2024 | +3.2% | +0.8% | -15.6% | |
| Q4 2023 | +24.4% | +12.7% | -8.2% | |
| Q3 2023 | +11.8% | +4.8% | -13.8% | |
| Q2 2023 | +2.6% | -9.9% | -28.0% | |
| Q1 2023 | -5.2% | -4.5% | -2.6% | |
| Q4 2022 | +7.0% | +3.0% | -20.8% | |
| Q3 2022 | -34.2% | -13.7% | -31.5% | |
| Q2 2022 | +17.5% | +31.2% | +47.0% | |
| Q1 2022 | -4.4% | +12.8% | +15.2% | |
| Q4 2021 | -20.1% | -4.3% | -19.7% | |
| Q3 2021 | -2.7% | -7.8% | -34.7% | |
| Q4 2020 | -1.4% | +5.5% | +7.5% | |
| Q2 2021 | -10.7% | -11.9% | +10.1% | |
| Q1 2021 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro